P Wilfredo Canchis, MD
Internal Medicine · Johnston, RINPI 1518018811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$467
- AbbVie$461
- GSK$416
- Indivior Inc.$412
- Ardelyx, Inc.$391
- AstraZeneca$276
- plus $2K from 23 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$4,55998%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $467 |
| AbbVie(2 entities) | 34 | $461 |
| GSK | 19 | $416 |
| Indivior Inc. | 18 | $412 |
| Ardelyx, Inc. | 21 | $391 |
| AstraZeneca | 16 | $276 |
| Phathom Pharmaceuticals, Inc. | 15 | $273 |
| Lilly USA, LLC | 14 | $250 |
| QOL Medical, LLC | 11 | $246 |
| Novo Nordisk | 13 | $245 |
| Aimmune Therapeutics, Inc. | 7 | $176 |
| Bayer | 9 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $127 |
| Amgen | 7 | $119 |
| Pfizer | 7 | $113 |
| Exact Sciences | 5 | $101 |
| Abbott | 4 | $72 |
| Genentech USA, Inc. | 3 | $58 |
| UCB, Inc. | 4 | $52 |
| Optinose US, Inc. | 2 | $48 |
| Alfasigma USA, Inc. | 2 | $40 |
| Merck | 3 | $37 |
| Novartis | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Celltrion USA Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$113
How this compares
$4,644 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 166 | $161,957 |
| MounjaroTirzepatide | 129 | $157,905 |
| OzempicSemaglutide | 102 | $148,282 |
| FarxigaDapagliflozin Propanediol | 52 | $60,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $52,930 |
| EliquisApixaban | 51 | $49,622 |
| JardianceEmpagliflozin | 28 | $25,276 |
| JanuviaSitagliptin Phosphate | 13 | $20,687 |
| TrulancePlecanatide | 14 | $15,698 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 125 | $14,027 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $13,970 |
| Mesalamine | 12 | $7,002 |
| Omeprazole | 348 | $5,975 |
| Atorvastatin Calcium | 300 | $4,143 |
| Sucralfate | 28 | $2,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $461 | $161,957166 claims |
| Lilly USA, LLCMounjaro | $250 | $157,905129 claims |
| Novo NordiskOzempic | $245 | $148,282102 claims |
| AstraZenecaFarxiga | $276 | $60,86652 claims |
| GSKTrelegy Ellipta | $416 | $52,93078 claims |
| PfizerEliquis | $113 | $49,62251 claims |
| MerckJanuvia | $37 | $20,68713 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $467 | $15,69814 claims |
| Indivior Inc.Suboxone | $412 | $13,97046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Johnston
- Kathleen GordonJohnston$16K
- Stephanie DrainvilleJohnston$11K
- Kiley ToderJohnston$7K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.